2, 95%CI8.2,36.2] and processing of labels (e.g., reading labels AOR=2.6, 95%CI1.8,3.7), and consumer reports of drinking less due to the labels (AOR=3.7, 95%CI 2.0,7.0). Strengthening health messages on alcohol containers can achieve their goal of attracting attention, deepening engagement, and enhancing motivation to reduce alcohol use. Strengthening alcohol labelling policies should be a priority for alcohol control globally. Crown V. All rights reserved.AIM To investigate the nationwide time trends in incidence and survival of oesophageal and gastric adenocarcinomas according to the Laurén classification (intestinal, diffuse and mixed type). METHODS All patients diagnosed in the Netherlands with oesophageal or gastric adenocarcinoma between 1989 and 2015 were included. A syntax was developed to determine the histological subtype based on pathology reports as archived in the Dutch pathology registry. These reports were linked to individual data from the Netherlands Cancer Registry. Relative survival was used to assess survival. RESULTS The histological subtype could be determined in 18.691 (84.1%) oesophageal and in 32.312 (83.5%) gastric adenocarcinomas. https://www.selleckchem.com/products/NPI-2358.html Among these, 79% were intestinal and 21% diffuse type in oesophageal cancers, compared to 55% intestinal and 44% diffuse type in gastric cancers. Relative median survival of intestinal type tumours was longer than that of diffuse type tumours, that is, 12.1 versus 9.4 months for oesophageal carcinomas, and 10.1 versus 7.6 months for gastric carcinomas, respectively. Between 1989 and 2015, the relative median survival of non-metastatic intestinal and diffuse type oesophageal adenocarcinoma improved from 12.0 to 30.0 months, and from 12.0 to 19.2 months, respectively. The same was true for intestinal type gastric carcinoma (from 22.8 to 27.6 months) but for diffuse type gastric carcinoma, the increase was less (from 16.8 to 18.0 months). CONCLUSION In this nationwide study, histological subtypes of oesophageal and gastric adenocarcinomas differed in incidence and survival times. These findings may call for a differentiated treatment approach. BACKGROUND The evidence of combining neoadjuvant chemotherapy with targeted therapy for patients with locally advanced gastric cancer is inadequate. We conducted a single-arm phase II trial to evaluate the efficacy and safety of S-1, oxaliplatin and apatinib (SOXA) in patients with locally advanced gastric adenocarcinoma. METHODS Treatment-naïve patients received three preoperative cycles of S-1 (80-120 mg/day on days 1-14) and oxaliplatin (130 mg/m2 on day 1) and two cycles of apatinib (500 mg/day for 21 days) at 3-week intervals, followed by surgery. The primary end-point was pathologic response rate (pRR). This trial is registered at ChiCTR.gov.cn ChiCTR-OPC-16010061. RESULTS Of 29 patients included, median age was 60 (range, 43-73) years; 20 (69.0%) were male. The pRR was 89.7% (95% confidence interval [CI], 72.7%-97.8%; 26 of 29 patients; P  less then  0.001) with 28 patients treated with surgery. All 29 patients were available for preoperative response evaluation, achieving an objective response rate of 79.3% (95% CI, 60.3%-92.0%) and a disease control rate of 96.6% (95% CI, 82.2%-99.9%). The margin-free resection rate was 96.6% (95% CI, 82.2%-99.9%). The pathologic complete response rate was 13.8% (95%CI, 1.2%-26.3%). Downstaging of overall TNM stage was observed in 16 (55.2%) patients. During neoadjuvant therapy, 10 (34.5%) patients had grade ≥III adverse events. No treatment-related death occurred. Surgery-related complications were observed in 12 of 28 (42.9%) patients. CONCLUSION SOXA followed by surgery in patients with locally advanced gastric adenocarcinoma showed favourable activity and manageable safety. A randomised controlled trial in locally advanced gastric or oesophagogastric junction adenocarcinoma is ongoing (ClinicalTrials.gov NCT04208347). The ever-growing threats of multidrug-resistant bacterial infection and chronic wound healing have created an imperative need for the development of novel antibacterial materials and therapeutic strategies, especially for diabetic patients infected with multidrug-resistant bacteria. In this work, the nanocomplexes named as PB@PDA@Ag were used for eradicating multidrug-resistant bacteria and accelerating wound healing of MRSA-infected diabetic model with the assistance of laser irradiation. In vitro results revealed that the combinational strategy exerted a synergistic effect for anti-MRSA through disrupting cell integrity, producing ROS, declining ATP, and oxidizing GSH, comparing with PB@PDA@Ag or NIR laser irradiation alone. Moreover, in vivo assay demonstrated that this system effectively accelerated MRSA-infected diabetic wound healing by mitigating local inflammatory response and up-regulating VEGF expression on the wound bed. Meanwhile, satisfactory biocompatibility and negligible damage to major organs were observed. Altogether, the aforementioned results indicate that the combinational therapy of PB@PDA@Ag and NIR irradiation shows a great potential application in the field of clinic infection. Delivery of ophthalmic drugs to the interior parts of the eye for effective treatment of glaucoma (i.e., a chronic disease) remains a huge challenge because of the well-known static and dynamic ocular barriers. Herein, we present a new antiglaucoma formulation based on the development of a dual-functional therapeutic nanocarrier platform for intraocular targeted and sustained delivery of pilocarpine. Specifically, chitosan and ZM241385 are functionalized onto surfaces of hollow ceria nanoparticles (hCe NPs), thereby endowing the nanocarriers with a strong capability to open corneal epithelial tight junctions and deliver drug molecules to the targeted intraocular tissue (i.e., ciliary body). Moreover, the nanocarriers are demonstrated in vitro and in vivo to possess potent anti-oxidant and anti-inflammatory properties, which are beneficial to simultaneously alleviate glaucomatous damage. Single topical instillation of the pilocarpine-loaded dual-functional therapeutic nanocarriers with optimized delivery performance onto experimentally glaucomatous eyes can effectively mitigate disease progression for 7 days while that employing the traditional commercial eye drops only provides a moderate treatment efficacy for 4 h, possibly due to improved intraocular drug delivery (~250-fold greater bioavailability in the ciliary body) and intrinsic therapeutic activity of the ophthalmic formulation.